Alimera Sciences Inc (NASDAQ:ALIM) had its price objective raised by investment analysts at Cantor Fitzgerald from $6.00 to $10.00 in a research note issued to investors on Tuesday, StockTargetPrices.com reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 383.09% from the […]
